Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TAK-491 when co-administered with amlodipine 5 mg in subjects with essential hypertension.

Next Previous
Trial Profile

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TAK-491 when co-administered with amlodipine 5 mg in subjects with essential hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Amlodipine
  • Indications Essential hypertension; Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center

Most Recent Events

  • 01 Jun 2010 Results have been presented at the 20th European Meeting on Hypertension.
  • 01 May 2010 Results presented at 25th Annual Scientific Meeting of the American Society of Hypertension.
  • 03 Jul 2009 Actual patient number (566) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top